Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
about
Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trialsSo many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics.The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
P2860
Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Effect of the novel anxiolytic drug deramciclane on cytochrome P
@nl
Effect of the novel anxiolytic ...... desipramine pharmacokinetics.
@ast
Effect of the novel anxiolytic ...... desipramine pharmacokinetics.
@en
type
label
Effect of the novel anxiolytic drug deramciclane on cytochrome P
@nl
Effect of the novel anxiolytic ...... desipramine pharmacokinetics.
@ast
Effect of the novel anxiolytic ...... desipramine pharmacokinetics.
@en
prefLabel
Effect of the novel anxiolytic drug deramciclane on cytochrome P
@nl
Effect of the novel anxiolytic ...... desipramine pharmacokinetics.
@ast
Effect of the novel anxiolytic ...... desipramine pharmacokinetics.
@en
P2093
P1476
Effect of the novel anxiolytic ...... desipramine pharmacokinetics.
@en
P2093
Harry Björklund
Juha Rouru
Jutta Hänninen
Kari Laine
Markku Anttila
Steven De Bruyn
P2888
P304
P356
10.1007/S00228-003-0714-Z
P577
2004-01-17T00:00:00Z
P6179
1053131104